Translate

Κυριακή 16 Ιουνίου 2019

Thyroid Cancer Bone Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort
Purpose Bone metastasis (BM) in differentiated thyroid cancer (DTC) is the second most common site of metastasis after lung. Bone metastases are associated with worse prognosis in DTC. In this study, we examined risk factors for overall survival in patients with BM and for the first time explore the pattern of genomic alterations in DTC BM. Patients and Methods A Health Insurance Portability and Accountability Act (HIPAA) compliant, institutional review board–approved retrospective evaluation of the medical record was performed for all patients treated at a single institution for thyroid cancer over a 16-year period. Seventy-four patients met inclusion criteria. Multiple prognostic factors including age, sex, genes, radioactive iodine, and radiation or kinase inhibitor therapies were analyzed. Univariate and multivariate analyses were performed. Results Treatment with external beam radiation was found to significantly increase survival (P = 0.03). The 5-year survival rate was 59% and median survival was 92 months. Patients who developed bone metastasis earlier tend to live longer (P = 0.06). The presence of TERT and BRAF mutations did not significantly worsen the prognosis (P = 0.10). Conclusion Patients with DTC can benefit from early treatment with external beam radiation therapy, especially those who develop bone metastasis within 3 years of primary TC diagnosis. Kinase inhibitor treatment tended to prolong survival but not in a statistically significant manner. Sex, age, and TERT or BRAF genetic mutations did not significantly affect the prognosis. Received for publication October 26, 2018; revision accepted March 30, 2019. Conflicts of interest and sources of funding: This study was supported by R01 CA201250-01A1 “124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer” Grant (JRO, RKG, SML) as well as by the Center for Targeted Radioimmunotherapy and Diagnosis and the Ludwig Center for Cancer Immunotherapy. This research was also funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. None declared to all authors. Correspondence to: Joseph R. Osborne, MD, PhD, Chief of Nuclear Medicine Department of Radiology New York—Presbyterian Weill Cornell Medical Center 520 E 70th Street, Starr-2, New York, NY 10021. E-mail: jro7001@med.cornell.edu. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου

Translate